Latest News - Amgen

Top Corporates Hub

Amgen

AMGN | NASDAQ | United States
102
-28
Rank
$166.77B
Market Cap
$33.42B
+$ 1.1B
+3.4%
Revenue
$4.60B
-$ 3.25B
-41.4%
Earnings
28K
+1.3K
+4.87%
Employees
Stock Market News for Sep 9, 2026

09.09.2026 11:11

Wall Street ended lower as market participants weighed inflation concerns, rising oil prices and interest-rate expectations.

Read More

Amgen, AstraZeneca combination improves survival measures in late-stage lung cancer study

09.09.2026 10:10

Amgen Inc. (NASDAQ:AMGN) and AstraZeneca PLC (LSE:AZN) said a late-stage study of Imdelltra combined with Imfinzi produced improved outcomes in patients with extensive-stage small-cell lung cancer.

Read More

Pyxis Oncology Stock Soars Over 5% Overnight: Here's What You Need to Know

09.09.2026 04:01

Pyxis Oncology shares gained 9.25% after hours following a leadership update and ahead of Wednesday’s clinical data webcast.

Read More

Novartis Late-Stage Cardiovascular Outcome Study Fails, Stock Down

07.09.2026 16:49

Novartis' pelacarsen study failed to cut cardiovascular events, clouding prospects for the drug and highlighting portfolio challenges.

Read More

Amgen Shares Fall as Novartis' Pelacarsen Misses Phase III Study Goal

07.09.2026 16:23

AMGN shares fall as NVS' pelacarsen setback casts investor concern over whether olpasiran can deliver positive phase III outcome data.

Read More

Amgen (AMGN) Says Repatha Reduced Mortality Before a First Heart Attack or Stroke. Can Earlier Use Expand the Market?

04.09.2026 15:59

Amgen Inc. (NASDAQ:AMGN) reported that Repatha reduced the risk of all-cause mortality by 20% in a prespecified secondary analysis of the Phase 3 VESALIUS-CV trial. The study enrolled more than 12,000 high-risk adults without a previous heart attack or stroke and followed them for a median of 4.6 years. The mortality reduction began to appear […]

Read More

J&J Faces Multiple Headwinds: Can the Healthcare Giant Sustain Growth?

02.09.2026 14:47

JNJ faces Stelara and upcoming drug LOEs, MedTech weakness and talc litigation, but targets accelerated growth in 2026 and beyond.

Read More

2026 Complement Inhibitors Market Analysis Report (2nd Edition) Featuring Amgen, CSL Behring, Innovent Biologics, Novartis, Regeneron, Roche, Sanofi, Takeda, UCB

02.09.2026 12:17

Complement Inhibitors Market Complement Inhibitors Market Dublin, Sept. 02, 2026 (GLOBE NEWSWIRE) -- The "Complement Inhibitors Market (2nd Edition): Distribution by Target Disease Indication, Therapeutic Area, Type of Molecule, Target Pathway, Type of Therapy, Route of Administration, Leading Drugs, Key Geographical Regions and Leading Players - Trends and Forecast Till 2035" has been added to ResearchAndMarkets.com's offering. The global complement inhibitors market is projected to increase fr

Read More

Cramer’s Stop Trading: Amgen

31.08.2026 09:59

CNBC’s Jim Cramer explains why he is keeping an eye on shares of Amgen.

Read More

Piper Sandler Maintains Overweight on Amgen, Raises Price Target to $457

20.08.2026 12:24

Piper Sandler analyst David Amsellem maintains Amgen (NASDAQ:AMGN) with a Overweight and raises the price target from $427 to $457.

Read More

BeOne Medicines Ltd (ONC) (Q2 2026) Earnings Call Highlights: Revenue Surges 30% to $1. ...

13.08.2026 01:04

BeOne Medicines Ltd (ONC) delivers robust Q2 2026 results with record BRUKINSA sales, raises full-year guidance, and advances a promising oncology pipeline.

Read More

Guggenheim Maintains Neutral on Amgen, Raises Price Target to $388

10.08.2026 09:43

Guggenheim analyst Vamil Divan maintains Amgen (NASDAQ:AMGN) with a Neutral and raises the price target from $343 to $388.

Read More

How to Build $13,000 a Month in Dividend Income From Three Income Buckets

10.08.2026 03:34

Reaching $13,000 a month in dividends sounds like a capital problem, but the real trap is choosing the wrong yield tier and watching income quietly erode while you sleep. Three buckets can get you there, each with a very different cost hiding beneath the headline number.

Read More

Amgen: The Market Is Underestimating Its Next Growth Phase

07.08.2026 10:51

Amgen stock update: Tezspire and Repatha sales are surging as 2026 revenue guidance rises. Click here to read more about AMGN.

Read More

Chubb, Toast And A Health Care Stock On CNBC’s ‘Final Trades’

07.08.2026 08:05

Bill Baruch chose Amgen Inc. as his final trade, citing its strong Q2 results and raised guidance. Malcolm Ethridge recommended Chubb.

Read More

Stock Market Today: Dow Rises, Nasdaq Slides As Tech Stocks Come Under Pressure; Uber Dives (Live Coverage)

05.08.2026 18:56

Stock Market Today: The Dow Jones index rises Wednesday with word on a Strait of Hormuz deal. AMD stock and SpaceX fall.

Read More

Amgen gains after strong quarterly results and continued product momentum

05.08.2026 17:25

Amgen Inc (NASDAQ:AMGN, XETRA:AMG) shares rose about 4% on Wednesday after the biotechnology company reported second quarter 2026 results that topped Wall Street expectations, supported by higher revenue and growth across its portfolio of medicines. The company reported adjusted earnings per...

Read More

Teva Pharmaceuticals: Continuing To Execute On Its 'Pivot To Growth' Plan

05.08.2026 16:05

Teva Pharmaceutical Industries Limited turnaround: Pivot to Growth, raised 2026 guidance, $3.7B specialty target, and more. Click for this TEVA update.

Read More

Amgen: First $10 Billion Quarter, More Growth Ahead

05.08.2026 14:21

Amgen Inc. Q2 beat lifts FY guidance despite LOE headwinds; see portfolio drivers, pipeline catalysts, and M&A limits—click to read the AMGN highlights now.

Read More

AMGN Q2 Earnings Call Centers on Raised Outlook and Pipeline

05.08.2026 14:00

Amgen raised its 2026 outlook as broad product growth funds a deeper late-stage pipeline push amid biosimilar pressure on older franchises.

Read More